Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis in multiple myeloma.

S V Rajkumar1, R A Kyle

  • 1Division of Hematology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA.

Seminars in Oncology
|December 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical mythology: Apollo.

Mayo Clinic proceedings·1992
Same author

Amyloidosis. Introduction and overview.

Journal of internal medicine·1992
Same author

Primary systemic amyloidosis.

Journal of internal medicine·1992
Same author

Wladyslaw Bieganski--father of modern Polish medicine.

Mayo Clinic proceedings·1992
Same author

Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients.

Archives of internal medicine·1992
Same author

Medical mythology: Hera (Juno).

Mayo Clinic proceedings·1992
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

New blood vessel formation (angiogenesis) is elevated in multiple myeloma, correlating with disease progression. Lower levels of angiogenesis are linked to longer survival, supporting anti-angiogenic therapies for myeloma.

Area of Science:

  • Oncology
  • Hematology
  • Pathology

Background:

  • Angiogenesis, or new blood vessel formation, is crucial for tumor growth and metastasis.
  • Multiple myeloma, a plasma cell cancer, exhibits increased angiogenesis compared to precursor conditions like monoclonal gammopathy of undetermined significance (MGUS).
  • Neoplastic plasma cells in multiple myeloma express angiogenic cytokines, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).

Purpose of the Study:

  • To investigate the role and significance of angiogenesis in the pathogenesis and progression of multiple myeloma.
  • To compare the level of angiogenesis in multiple myeloma with other plasma cell disorders.
  • To evaluate the correlation between angiogenesis grade and patient survival in multiple myeloma.

Main Methods:

Related Experiment Videos

  • Assessed microvascular density (MVD) in a cohort of 400 patients with various plasma cell disorders, including controls, MGUS, and different stages of myeloma.
  • Analyzed MVD in relation to disease status (smoldering, newly diagnosed, relapsed myeloma).
  • Correlated angiogenesis grade with overall survival in 74 newly diagnosed multiple myeloma patients.

Main Results:

  • Microvascular density (MVD) was significantly higher in smoldering, newly diagnosed, and relapsed multiple myeloma compared to controls, MGUS, and primary amyloidosis.
  • Patients with multiple myeloma showed higher angiogenesis than those with MGUS.
  • A significant correlation was observed between lower-grade angiogenesis and longer overall survival in newly diagnosed multiple myeloma patients.

Conclusions:

  • Increased angiogenesis is a hallmark of multiple myeloma and is associated with disease progression.
  • The level of angiogenesis correlates with patient prognosis, with lower levels indicating better survival.
  • These findings provide a strong rationale for developing and investigating anti-angiogenic therapies for multiple myeloma treatment.